Clinical Trial Search

Primary: Percentage of Participants That Report at Least 1 Solicited Injection-site Adverse Event (AE) — 45.3; 44.7; 41.9; 39.1 Percentage of Participants — p== 0.824

Primary: F3-F2 Distance, an Acoustic Measure That Correlates With Perceptual Accuracy of /r/, Measured From /r/ Sounds Produced in Treatment Sessions. — 1793.3; 1772.2 Hz — p=.67

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 6.0; 82.7; 0.0; 2.0 percentage of participants

Primary: Feasibility: Percentage of Patients Entering Any Exercise Data Into the Mobile App ≥50% of the Study Period Days, Excluding Hospitalization — 18; 14 Participants

Primary: Dose Limiting Toxicities (DLT) — 0; 1; 0 toxicities

Primary: Percentage of Participants With Successful Closure of Wound at 2 Weeks After Surgery — 85.7142857; 87.5 percent of participants

Primary: Intervention Acceptability — 2; 5; 40 Participants

Primary: Weight Loss Kg — -0.53; -4.37 kg

Primary: Recruitment as Measured by Rates of Enrollment (Aim 1) — 120; 95; 22; 2 Participants

Primary: Dose Limiting Toxicity — 0; 0; 1; 0 Participants

Primary: Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43 — -2.64; -2.36 score on a scale — p=0.632

Primary: Progression Free Survival — 2.7; 3.1 months — p=0.04

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 19; 11; 5 Participants

Primary: Dogoxin Plasma Data for Cmax — 1530.188; 2432.908 pg/mL

Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage